Industrial Solutions revenue: $45.4 million, +1.6% YoY; Aerospace & Defense delivered >20% YoY growth, partially offset by lower demand in jewelry due to Middle East conflict (CFO).
Healthcare Solutions revenue: $50.1 million, +21% YoY, surpassing Industrial as the larger segment; driven by Dental and Med Tech (CFO).
Non-GAAP gross margin: 36.1%, up 6 ppts YoY (adjusted for software divestitures), driven by higher volume, favorable consumables mix, improved printer margins, and cost initiatives (CFO).
Non-GAAP operating expenses: $36.6 million, down 35% YoY (adjusted for divestitures) and down 11% sequentially; >$55 million in annualized cost savings delivered through Q1 (CFO).
Adjusted EBITDA: positive $2.1 million, an improvement of $26 million YoY ($28.2 million adjusted for divestitures) (CFO).
Non-GAAP loss per share: ($0.01), improved from ($0.21) in prior year (CFO).
Cash: $86.5 million total cash ($85.1 million cash & equivalents, $1.4 million restricted cash); $3.9 million debt due Q4 2026, $92 million maturing 2030 (CFO).
Aerospace & Defense: expected >20% growth in 2026, equating to ~$35 million in revenue; driven by space, naval, aero propulsion, UAVs, and precision munitions (CEO).
NextDent 300 denture platform: most successful new product launch in 5 years; solid order backlog into Q2; internal production targets raised for H2; EU Phase IIa approval received 2 months ahead of schedule (CEO).
Littleton facility expansion: adding 80,000 sq ft of manufacturing space for metal components; grand opening on track for late summer (CEO).
Official Guidance
Q2 2026 revenue: $93 million to $95 million (CFO).
Q2 2026 adjusted EBITDA loss: $2 million to $4 million (CFO).
Full-year 2026: expect to achieve breakeven adjusted EBITDA or better (CEO).
Mgmt Quotes
"The additive manufacturing industry is now beginning to emerge from a multiyear trough driven largely by global economic and geopolitical challenges." (CEO)
"The NextDent 300 has been the most successful new product launch since my arrival at 3D Systems 5 years ago, with very few installation issues, rapid integration in lab workflows and acceptance by dentists often upon initial exposure to the product." (CEO)
"Given our unmatched breadth of defense-focused printing technology, we continue to expect over 20% growth in our Aero & Defense markets this year, equating to approximately $35 million in revenue in 2026." (CEO)
"We continue to demonstrate strong cost management discipline as we move into 2026." (CFO)
"We expect to build on our top-line growth momentum in key markets over the coming quarters while maintaining strong cost discipline to achieve breakeven adjusted EBITDA or better for the full year." (CEO)
Prepared Metrics
Metric
Value
Speaker/Context
Consolidated revenue
$95.5 million, +11% YoY
CFO
Industrial Solutions revenue
$45.4 million, +1.6% YoY
CFO
Healthcare Solutions revenue
$50.1 million, +21% YoY
CFO
Non-GAAP gross margin
36.1%, +6 ppts YoY
CFO
Non-GAAP operating expenses
$36.6 million, -35% YoY
CFO
Adjusted EBITDA
$2.1 million
CFO
Non-GAAP loss per share
($0.01)
CFO
Total cash
$86.5 million
CFO
Q2 2026 revenue guidance
$93M–$95M
CFO
Q2 2026 adjusted EBITDA guidance
($2M)–($4M)
CFO
Aero & Defense 2026 revenue expectation
~$35 million
CEO
Q&A Batch (1-2 of 2)
Q1 — Greg Palm
Topic: Growth outlook, Q2 revenue guidance, and EBITDA profitability
Key points:
Management tone is more positive due to R&D spend maintained over past few years, resulting in a refreshed product line coinciding with 3D printing regaining traction.
Green shoots are broad across markets: Dental (going custom/3D printing), Med Tech (orthopedic space expanding), and Aerospace & Defense (benefiting from 3D printing for exotic materials).
Q1 revenue beat guidance due to a legitimate uptick in demand, with no pull-forwards; Q2 will see normal seasonal dip (especially in Healthcare, as dental/orthopedic procedures drop in spring/summer).
Q1 achieved EBITDA profitability; stable OpEx expected, implying EBITDA roughly breakeven in Q2 based on guide, but management is measured due to global volatility (Middle East logistics issues).
Mgmt stance: Bullish but cautious — positive on new products and broad market traction, but keeping guidance realistic due to geopolitical uncertainty and seasonal patterns.
Q2 — Troy Jensen
Topic: Healthcare business growth and metal additive parts expansion
Key points:
Healthcare (Med Tech + Dental) both strong in Q1; Med Tech (personalized health care, surgical planning, implants) is a double-digit organic grower year-on-year, driven by faster response times for trauma and oncology (bone cancer treatment with PEEK implants).
Dental growth driven by Vertex material trademark approval in the U.S. (resolved in Q4) for tooth repair, plus stabilization in teeth straightening.
Metal additive parts: Expanding Littleton facility by 80,000 sq ft (adjacent building) for industrial part manufacturing, focused on aerospace (titanium, zirconium, nickel-based alloys for propulsion, copper-nickel for Navy). Grand opening expected late July/early August.
Mgmt stance: Bullish — Healthcare is a favorite due to regulatory barriers and consistent growth; metal parts demand exceeds current capacity, justifying expansion.